The stock of Mediwound Ltd (NASDAQ:MDWD) hit a new 52-week low and has $4.70 target or 6.00% below today’s $5.00 share price. The 6 months bearish chart indicates high risk for the $107.33M company. The 1-year low was reported on Nov, 24 by Barchart.com. If the $4.70 price target is reached, the company will be worth $6.44M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock decreased 5.66% or $0.3 on November 23, hitting $5. About 26,263 shares traded hands or 31.76% up from the average. Mediwound Ltd (NASDAQ:MDWD) has declined 39.47% since April 22, 2016 and is downtrending. It has underperformed by 44.88% the S&P500.
Analysts await Mediwound Ltd (NASDAQ:MDWD) to report earnings on January, 23. They expect $-0.25 earnings per share, up 30.56% or $0.11 from last year’s $-0.36 per share. After $-0.26 actual earnings per share reported by Mediwound Ltd for the previous quarter, Wall Street now forecasts -3.85% EPS growth.
Mediwound Ltd (NASDAQ:MDWD) Ratings Coverage
Out of 4 analysts covering MediWound (NASDAQ:MDWD), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $15 is the highest target while $13 is the lowest. The $14 average target is 180.00% above today’s ($5) stock price. MediWound has been the topic of 4 analyst reports since August 10, 2015 according to StockzIntelligence Inc. As per Monday, August 10, the company rating was reinitiated by Credit Suisse. The company was initiated on Wednesday, August 17 by Wells Fargo. SunTrust initiated the stock with “Buy” rating in Wednesday, March 23 report.
According to Zacks Investment Research, “MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel.”
Another recent and important Mediwound Ltd (NASDAQ:MDWD) news was published by Marketwatch.com which published an article titled: “Plus the latest data from Realtor.com on 21 home markets across the US” on March 21, 2014.
MDWD Company Profile
MediWound Ltd., Incorporated on January 27, 2000, is a biopharmaceutical firm focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns. NexoBrid is based on the Company’s proteolytic enzyme technology. It offers NexoBrid in Europe and Israel.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.